Last reviewed · How we verify
NCT04316520: CETOREIN
Ketogenic Diet for Patients Receiving Treatment for Metastatic Renal Cell Carcinoma
Completed
NA
Last updated 16 August 2024
What this trial tests
NA trial testing Ketogenic diet in Metastatic Renal Cancer in 20 participants. Completed in 6 March 2024.
Timeline
22 July 2020
Primary endpoint
6 January 2023
6 January 2023
6 March 2024
Quick facts
| Lead sponsor | University Hospital, Angers |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 22 July 2020 |
| Primary completion | 6 January 2023 |
| Estimated completion | 6 March 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Ketogenic diet — full drug profile →
Conditions studied
- Metastatic Renal Cancer — all drugs for Metastatic Renal Cancer →
Sponsor
University Hospital, Angers
Who can join
18 and older, any sex, with Metastatic Renal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the tolerance of one year of ketogenic diet associated with vitamin supplementation in patients treated for a metastatic renal cell carcinoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential.
Xiao YL, Gong Y, Qi YJ, Shao ZM, et al · · 2024 · cited 120× · PMID 38462638 · DOI 10.1038/s41392-024-01771-x -
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy.
Kang X, Lau HC, Yu J. · · 2024 · cited 65× · PMID 38631285 · DOI 10.1016/j.xcrm.2024.101478 -
Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer.
Montégut L, de Cabo R, Zitvogel L, Kroemer G. · · 2022 · cited 32× · PMID 35997502 · DOI 10.1158/2159-8290.cd-22-0504 -
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
Davar D, Zarour HM. · · 2022 · cited 32× · PMID 35748749 · DOI 10.1158/1078-0432.ccr-21-1129 -
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy.
Smith PL, Piadel K, Dalgleish AG. · · 2021 · cited 18× · PMID 34960140 · DOI 10.3390/vaccines9121392 -
Diet-gut microbial interactions influence cancer immunotherapy.
Wang X, Geng S. · · 2023 · cited 11× · PMID 37035188 · DOI 10.3389/fonc.2023.1138362 -
Microbiota and their metabolites potentiate cancer immunotherapy: Therapeutic target or resource for small molecule drug discovery?
Du P, Jing J, He X. · · 2022 · cited 6× · PMID 36588712 · DOI 10.3389/fphar.2022.1091124 -
Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review.
David A, Lev-Ari S. · · 2024 · cited 4× · PMID 39223798 · DOI 10.1177/15347354241269870
Verify or expand the search:
- PubMed search for NCT04316520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ketogenic diet
Trials testing the same drug.
- NCT07495267 — Nutritional Ketosis Marfan · NA · not yet recruiting
- NCT07415590 — Ketogenic Diet for Post-Traumatic Stress Disorder (PTSD) · NA · not yet recruiting
- NCT03991897 — Nutritional Ketosis: a Novel Metabolic Strategy to Treat Lymphedema Patients? · NA · recruiting
- NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting
- NCT06963437 — Interventions for Weight Regain After Bariatric Surgery · NA · completed
Other recruiting trials for Metastatic Renal Cancer
Currently open trials in the same condition.
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
- NCT06583070 — SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer · recruiting
- NCT05796973 — Measuring Oncological Value of Exercise and Statin · Phase 3 · recruiting
Other University Hospital, Angers trials
Trials by the same sponsor.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07470294 — Effectiveness of Different Surgical Techniques for Curative Treatment of Pilonidal Sinus Disease in the Pediatric Popula · not yet recruiting
- NCT07409597 — Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease · NA · not yet recruiting
- NCT07468565 — Surgical Approach for the Treatment of Hirschsprung Disease Using the Swenson Technique (SMILES) · not yet recruiting
- NCT07452952 — Relationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distre · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04316520 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Angers
- Last refreshed: 16 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04316520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing